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Abstract
Purpose To assess the potential inhibitory and inductive
eVects of azacitidine on cytochrome P450 isozymes in
vitro.
Methods The inhibitory eVects of azacitidine on various
CYP isozymes were determined in human liver micro-
somes. In addition, the ability of azacitidine to induce CYP
enzymes in cultured human hepatocytes was evaluated.
Results Azacitidine did not inhibit CYP2B6-, CYP2C8-,
CYP2C9-, CYP2C19-, CYP2D6-, and CYP3A4-mediated
activities in human liver microsomes up to a concentration
of 100 M, while weak inhibition (<30% inhibition) of
CYP1A2 and CYP2E1 activities was observed at 100 M
azacitidine. In vitro azacitidine did not induce CYP1A2,
CYP2C19, or CYP3A4/5 activities in cultured human hepa-
tocytes.
Conclusions Azacitidine is not an inhibitor or inducer of
the cytochrome P450 isozymes tested; therefore, clinically
relevant pharmacokinetic drug–drug interactions are
unlikely to occur between azacitidine and co-administered
substrates of these CYP isozymes.
Keywords Azacitidine · Cytochrome P450 · CYP 
inhibition · CYP induction · Drug–drug interactions
Introduction
Azacitidine (5-azacitidine) is an analogue of the naturally
occurring pyrimidine nucleoside cytidine possessing phar-
macological eVects on cell diVerentiation, gene expression,
and DNA synthesis and metabolism [1–4]. Mechanistically,
azacitidine is believed to exert its antineoplastic eVects by
causing hypomethylation of DNA and direct cytotoxicity
on abnormal hematopoietic cells in the bone marrow [4, 5].
Azacitidine is used for the treatment of all subtypes of
myelodysplastic syndrome. It has also demonstrated activ-
ity for the treatment of acute myelogenous leukemia [6, 7].
Cytochrome P450 (CYP) is a superfamily of mixed
function oxidases that are responsible for the metabolism of
many drugs including oral contraceptives, dexamethasone,
and many anticancer agents such as taxanes. Some of these
enzymes are polymorphically expressed (e.g., CYP2D6,
CYP2C19) resulting in wide variability of pharmacokinet-
ics of their substrate drugs. CYP isozymes are subject to
inhibition via competitive or other mechanisms by drugs
such as ketoconazole, ritonavir, and clarithromycin, leading
to clinically relevant increases in the exposure of the
aVected drug. Further, some of the CYP isozymes are also
subject to induction by xenobiotics via activation of nuclear
receptors, with a consequent result of decreased exposure
of the aVected compound (e.g., rifampicin and oral contra-
ceptive steroids) leading to therapeutic failure or toxicolog-
ical implications due to higher levels of an undesired
metabolite [8, 9].
For a new molecular entity, it is important to assess its
likely inhibitory or inductive eVects on the metabolic reac-
tions catalyzed by CYP isozymes. Anticancer therapeutic
regimens often involve polypharmacy comprising of multi-
ple therapeutic agents and/or palliative therapies. Recent
clinical studies have explored combinations of azacitidine
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with other anticancer agents to enhance the therapeutic
activity [10–13]. It is likely that azacitidine will be admin-
istered with other therapeutic agents in clinical settings.
This study was conducted to evaluate the potential for
drug–drug interactions with azacitidine as an inhibitor or
inducer of CYP enzymes. The clinical dosing regimen of
azacitidine is by subcutaneous injection or intravenous
infusion of 75 mg/m2 for 7 days every 4 weeks (Vidaza®
package insert). The peak plasma concentrations of azaciti-
dine at the therapeutic dose are approximately 3 M [14,
15]. The concentrations of azacitidine employed in this
study span and exceed the therapeutic concentration range.
Materials and methods
Azacitidine was synthesized by Ash StevensTM (Riverview,
MI). Pooled human liver microsomes were obtained from
In Vitro Technologies (NJ, USA), Tissue Transformation
Technologies (T3) (NJ, USA), BD Biosciences Discovery
Labware (Woburn, MA), and CellzDirectTM Invitrogen
Corporation (Durham, NC). NADPH was purchased from
Sigma–Aldrich Co Ltd (St. Louis, USA). NADP+  (diso-
dium salt) and glucose 6-phosphate (disodium salt) were
obtained from Roche Products Ltd (Herts, UK), and glu-
cose 6-phosphate dehydrogenase (from yeast) was obtained
from Roche Diagnostics Ltd (East Sussex, UK). All radio-
labelled substrates were purchased from Amersham Phar-
macia Biotech UK Ltd (Bucks, UK). S-mephenytoin was
purchased from Gentest Corp (Woburn, MA). 4-Hydroxy-
mephenytoin was purchased from Research Biochemicals
International (Natick, MA). ResoruWn and 7-ethoxyres-
oruWn were purchased from Molecular Probes (Junction
City, OR). All other reagents including rifampin, -napht-
hoXavone (BNF), and testosterone were obtained from
Sigma–Aldrich Chemical Company, UltraWne Chemicals
Ltd (Manchester, UK), AYniti Research Products Ltd
(Exeter, UK), FSA Laboratory Supplies (Loughborough,
UK), BDH Ltd (Poole, UK), Helget Gas (Kansas City,
MO), Gibco BRL (Grand Island, NY), Pierce Chemical Co
(Rockford, IL), J.T. Baker Inc. (Phillipsburg, NJ), Fisher
ScientiWc (Pittsburgh, PA), Cohesion (Santa Clara, CA),
and Toronto Research Chemicals Inc (North York, ON,
Canada). All chemicals were of analytical grade or higher.
Inhibitory eVect on cytochrome P450s
Stock solution of azacitidine and subsequent serial dilutions
were freshly prepared and refrigerated until use. Other
stock solutions of substrates and inhibitors were made in
either aqueous or organic solvents, and the Wnal percentage
of organic solvent in incubation mixture was less than 1%.
Incubations were conducted at 37°C either in pH 7.4 potas-
sium phosphate buVer or Tris buVer in the presence of
human liver microsomes (concentrations from 0.05 to
2 mg/mL) and azacitidine at concentrations ranging from
0.1 to 100 M. The incubation mixture was preincubated
for 5 min prior to the initiation of metabolic reaction with
NADPH cofactor, in either duplicate or triplicate (CYP2B6
and CYP2C8), alongside vehicle control. After incubation,
the reactions were terminated by addition of quenching
reagents such as acetonitrile, hydrochloric acid, or per-
chloric acid. Incubation conditions for evaluating CYP
inhibition are summarized in Table 1. Experiments with
positive control inhibitors were conducted in parallel, and
furafylline as an inhibitor for CYP1A2 was preincubated
for 15 min prior to initiation with substrate.
Inductive eVect on cytochrome P450s
Human hepatocytes were prepared from three non-trans-
plantable human liver tissue samples procured from Blue
Color ScientiWc (Chapel Hill, NC). Fresh hepatocytes were
isolated and cultured according to established methods [16–
20]. Hepatocytes were seeded (approximately 1 million
hepatocytes per mL) on 60-mm Permanox culture dishes
(Fisher ScientiWc, Pittsburgh, PA), coated with collagen
(PureCol), and placed in a humidiWed culture chamber
(37 § 1°C, at 95% relative humidity, 95/5% air/CO2). After
an attachment period of 2–3 h, media and dead or unat-
tached cells were removed by aspiration, and the media
were replaced with modiWed Eagle’s medium Dr. Chee’s
modiWcation containing ITS+ (6.13 g/mL insulin,
6.13 g/mL transferrin, and 6.13 ng/mL selenous acid), lin-
oleic acid (5.25 g/mL), BSA (1.23 mg/mL), penicillin
(49 U/mL), streptomycin (49 g/mL), dexamethasone
(0.098 M), and Matrigel (250 g/mL). The viability of
hepatocytes was assessed by the trypan blue exclusion
method. Cultures were allowed to adapt to the culture envi-
ronment for 3 days with daily media replacement. Hepato-
cyte cultures were treated once daily for three consecutive
days, with medium containing 0.1% dimethyl sulfoxide
(DMSO) (vehicle, negative control), one of the three con-
centrations of azacitidine (1.0, 10 or 100 M), or one of the
two known human CYP enzyme inducers (positive con-
trols: 33 M -naphthoXavone and 20 M rifampin). At the
end of the treatment period, microsomal samples were pre-
pared and stored at ¡80°C until analysis. Microsomal incu-
bation was carried out with the CYP1A2, CYP2C19, and
CYP3A4/5 isozyme-speciWc probe substrates at the con-
centrations and incubation conditions indicated in Table 2.
The assessment of three CYP1A2, 2C19, and 3A4/5 activi-
ties was carried out as nuclear receptors, such as the aryl
hydrocarbon receptor (AhR), pregnane X receptor (PXR),
and constitutive androstane receptor (CAR), have been rec-
ognized as key mediators of drug-induced changes in theCancer Chemother Pharmacol (2010) 65:995–1000 997
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expression of CYP1A, CYP3A, CYP2B, and the CYP2C
enzymes. All incubations were conducted in duplicate wells
at 37 § 1°C in incubation mixtures containing potassium
phosphate buVer (50 mM, pH 7.4), MgCl2 (3 mM), EDTA
(1 mM), NADP (1 mM), glucose-6-phosphate (5 mM), and
glucose-6-phosphate dehydrogenase (1 Unit/ mL). Reactions
Table 1 Inhibitory eVect of azacitidine on isozyme-speciWc cytochrome P450 activities in human liver microsomes
NI No inhibition, DI Direct inhibition, HPLC High performance liquid chromatography, MS Mass spectrometry, PPB potassium phosphate buVer
* Azacitidine concentration range for each CYP isozyme was 0.1–100 M
CYP isozyme: SpeciWc 
probe activity, 
probe concentration
Incubation time (min); 
HLM concentration (mg/mL); 
BuVer
Analytical method Azacitidine*; 
positive control 
inhibitor concentration (m)
Percent 
inhibition 
or IC50
CYP1A2:
EthoxyresoruWn 
O-deethylation, 0.4 M
3; 0.1; 50 mM PPB Fluorescence 
ex = 530 nm, 
em = 585 nm
Azacitidine (0.1–100) 
Furafylline (10)
19.4% at 
100 M; 
53.7%
CYP2C9:
Tolbutamide 4-methyl 
hydroxylation, 100 M
30; 2; 50 mM Tris HPLC–UV/-Ram 
Radiochemical
Azacitidine (0.1–100) 
Sulfaphenazole (10)
NI; 80.4%
CYP2C19:
S-mephenytoin 
4-hydroxylation, 96.4 M
30; 2; 100 mM Tris HPLC–UV/-Ram 
Radiochemical
Azacitidine (0.1–100) 
Tranylcypromine (50)
NI; 51.8%
CYP2E1:
Chlorzoxazone 
6-hydroxylation, 40 M
15; 0.8; 50 mM PPB HPLC–UV (297 nm) Azacitidine (0.1–100) 
Diethyldithiocarbamate (50)
27.1% at 
100 M; 
75.0%
CYP2D6:
Bufuralol 
1-hydroxylation, 10 M
30; 0.05; 100 mM PPB HPLC-Fluorescence, 
ex = 252 nm, 
em = 302 nm
Azacitidine (0.1–100) 
Quinidine (1)
NI; 80.8%
CYP2B6:
Bupropion 
Hydroxylation, 50 M
20; 0.25; 100 mM PPB HPLC–MS/MS Azacitidine (0.1–100) 
DI: Orphenadrine
NI; 195 M
CYP2C8:
Paclitaxel 
6-hydroxylation, 10 M
10; 0.5; 100 mM PPB HPLC–MS/MS Azacitidine (0.1–100) 
DI: Montelukast
NI; 0.46 M
CYP3A4:
Testosterone 
6-hydroxylation, 65 M
10; 0.4; 50 mM PPB HPLC–UV/-Ram 
Radiochemical
Azacitidine (0.1–100) 
Ketoconazole (1)
NI; 70.8%
Table 2 Experimental conditions for CYP induction study
HPLC–UV high performance liquid chromatography–ultraviolet detection
Ref [26, 27] for additional details
CYP enzymes: CYP1A2 CYP2C19 CYP3A4/5
CYP-mediated reactions: 7-EthoxyresoruWn 
O-dealkylation
S-mephenytoin 
4-hydroxylation
Testosterone 
6-hydroxylation
Microsome content; incubation time 0.1 mg; 30 min 0.04 mg; 240 min 0.05 mg; 20 min
Organic solvent (% in incubation
mixture)
DMSO (0.4%) Methanol (1.2%) Methanol (2%)
Substrate; concentration 7-ethoxyresoruWn; 10 M S-mephenytoin; 400 M Testosterone; 250 M
Reaction stop reagents Acetone Methanol Methanol
Metabolites monitored ResoruWn4 -hydroxy-mephenytoin 6-hydroxy-testosterone
Analytical method Fluorimetric ex = 535 nm,
em =5 8 5n m
HPLC–UV (204 nm) HPLC–UV (254 nm)998 Cancer Chemother Pharmacol (2010) 65:995–1000
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were initiated by addition of the NADPH-generating sys-
tem and were terminated after the appropriate incubation
time by addition of acetonitrile. Precipitated protein was
removed by centrifugation (920 g for 10 min at 10°C), and
supernatants were analyzed for the respective metabolites
(Table 2). The catalytic activities in cultures treated with
azacitidine and positive control inducers were compared to
DMSO-treated cultures. A one-way analysis of variance
(ANOVA) for repeated measures was carried out to deter-
mine whether there were signiWcant diVerences between the
group means. The ANOVA was followed by a Dunnett’s
post hoc test to identify the group means that were signiW-
cantly diVerent from the controls (P < 0.05 or 5% level of
signiWcance). This statistical test is designed for multiple
comparisons with a mean, such as comparing multiple
treatment groups with a control group. Statistical analyses
were performed using SigmaStat Statistical Analysis
System (version 2.03, SPSS Inc, Chicago, IL).
Results
Inhibitory eVects on cytochrome P450s
The eVect of azacitidine on isozyme-speciWc CYP activities
in human liver microsomes is summarized in Table 1. As
expected, all positive control inhibitors produced inhibitory
eVects on the respective catalytic activities. Azacitidine did
not inhibit CYP2B6-, CYP2C8-, CYP2C9-, CYP 2C19-,
CYP2D6- and CYP3A4-mediated activities up to 100 M
concentration under the in vitro conditions tested. Although
limited inhibition of CYP1A2-dependent ethoxyresoruWn
O-dealkylation (19%) and CYP2E1-dependent chlorzoxa-
zone 6-hydroxylation (27%) was observed at the highest
concentration of azacitidine (100 M) tested, no inhibition
of these two CYP enzymes was observed at 70 M or lower
concentrations of azacitidine tested.
Inductive eVects on cytochrome P450s
At the time of isolation, the viability of each hepatocyte
preparation was between 73 and 89%. During the adapta-
tion followed by a 72-h incubation period, human cultured
hepatocytes were judged to be morphologically normal and
adequately conXuent for treatment with test and control
articles. In general, the cells were characteristically cuboi-
dal and contained intact cell membranes and granular cyto-
plasm with one or two centrally located nuclei. Enzymatic
activities (pmol/mg protein/min) and fold-over DMSO (nega-
tive control) data are listed in Table 3. As expected, the pos-
itive control inducers produced marked elevations in most
of the isozyme-speciWc catalytic activities tested. For all
three CYP isozymes tested, (CYP1A2, CYP2C19, and
CYP 3A4/5) treatment of azacitidine at 1 and 10 M
resulted in catalytic activities that were 0.86–1.20-fold of
the catalytic activities of the vehicle-treated cultures, dem-
onstrating no notable inductive eVect of azacitidine. At
100 M azacitidine, the CYP enzyme activities showed a
29% decrease of CYP1A2-mediated 7-ethoxyresoruWn
O-dealkylation, 56% decrease of CYP2C19-catalyzed
S-mephenytoin 4-hydroxylation, and a 78% decrease of
CYP3A4/5-catalyzed testosterone 6-hydroxylation. How-
ever, only the CYP3A4/5 activity decrease was statistically
signiWcant. Though morphologically azacitidine-treated
hepatocytes were observed to be similar to those of vehicle-
treated hepatocytes, it is possible that azacitidine, being a
cytotoxic compound, may have adverse eVects on primary
hepatocytes at high concentrations. Overall, the results of
this study demonstrate that treatment of cultured human
hepatocytes with clinically relevant concentrations of
Table 3 EVect of azacitidine on isozyme-speciWc cytochrome P450 enzymatic activities in cultured human hepatocytes
v/v volume/volume, DMSO dimethyl sulfoxide
a Values are the mean § standard deviation of three human hepatocyte preparations
* SigniWcantly diVerent from control (0.1% DMSO) according to Dunnett’s test (P <0 . 0 5 )
Treatment Concentration Enzymatic activity (pmol/mg protein/min)a (Mean fold over control)
7-EthoxyresoruWn 
O-dealkylation 
(CYP1A2)
S-mephenytoin 
4-hydroxylation 
(CYP2C19)
Testosterone 
6-hydroxylation 
(CYP3A4/5)
DMSO 0.1% (v/v) 4.09 § 0.86 7.80 § 0.78 4190 § 1350
Azacitidine 1 M4 . 1 1 § 0.94 (1.0) 9.47 § 4.76 (1.2) 4570 § 1960 (1.1)
Azacitidine 10 M3 . 7 8 § 0.72 (0.93) 6.82 § 2.89 (0.86) 3650 § 1320 (0.86)
Azacitidine 100 M2 . 9 1 § 0.77 (0.71) 3.51 § 1.16 (0.44) 936 § 443* (0.22)
-NaphthoXavone 33 M 36.3 § 1.5* (9.2) 33.6 § 13.6* (4.4) 1880 § 1150 (0.42)
Rifampin 20 M6 . 7 5 § 1.29* (1.7) 59.0 § 10.2* (7.5) 13100 § 200* (3.3)Cancer Chemother Pharmacol (2010) 65:995–1000 999
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azacitidine, once daily for three consecutive days, did not
induce CYP1A2, CYP2C19, and CYP3A4/5 activities.
Discussion
Azacitidine is shown to undergo non-enzymatic degrada-
tion to N-formylamidinoribosyl guanylurea and is sus-
ceptible for further decomposition both in vitro and in
vivo. In addition, cytidine deaminase and uridine-
cytidine kinase play a role in the metabolism of azaciti-
dine via deamination and phosphorylation, respectively
[21–24]. In humans, azacitidine and/or its metabolites
were eliminated renally, with 50–98% of the radioactive
dose recovered in urine [24], and CYP enzymes do not
play a role in metabolic clearance. Therefore, co-admin-
istration of potent CYP inhibitors (e.g., ketoconazole,
Xuconazole, Xuoxamine, and quinidine) or inducers is not
likely to result in clinically relevant eVects on the
exposure of azacitidine.
Based on early promising results in recent in vitro and in
vivo studies, azacitidine could potentially be administered
with other anticancer drugs in clinical settings [10, 12, 25],
some of which are likely to be CYP substrates. It is impor-
tant to understand any potential drug–drug interactions due
to inhibition or induction of CYP enzymes by azacitidine.
The results of these studies demonstrate that azacitidine
does not inhibit or induce CYP enzymes in vitro. The peak
plasma concentrations of azacitidine at therapeutic dose are
approximately 3 M, which are considerably lower than the
highest concentration (100 M) evaluated in this in vitro
study. Hence, azacitidine is not anticipated to precipitate
clinically relevant pharmacokinetic drug–drug interaction
when co-administered with CYP substrates either due to
inhibition or induction.
Conclusion
Azacitidine is not an inhibitor CYP enzymes nor inducer of
CYP group of enzymes via activation of AhR, CAR, or
PXR nuclear receptors; therefore, clinically relevant phar-
macokinetic drug–drug interactions are unlikely to occur
between azacitidine and co-administered substrates of these
CYP isozymes.
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